Abstract
There is increasing evidence that acute bacterial and viral infection represent trigger factors that temporarily elevate the risk of ischemic stroke. During and after influenza epidemics vascular death rates and hospitalizations for stroke are increased. Influenza vaccination is an effective measure to reduce hospitalization and mortality in the elderly and work incapacity in adults of working age. Results of several observational studies support the hypothesis that influenza vaccination is associated with reduced odds of stroke. As randomized studies are lacking, a causal role of influenza vaccination in stroke prevention is not proven, however. According to current guidelines in many countries, that recommend the vaccination in all patients with chronic vascular disease, all patients with a history of stroke or TIA should receive an influenza vaccination annually. Furthermore, patients with diabetes mellitus or with a combination of risk factors that increase stroke risk should obtain the vaccination. In addition, there is evidence from observational data that the neuraminidase inhibitor oseltamivir reduces the risk of stroke within 6 months after influenza infection.
Keywords: Acute infections, influenza, stroke, risk factor, cerebral ischemia, vascular disease, vaccination, antivirals
Infectious Disorders - Drug Targets
Title: Influenza and Stroke Risk: A Key Target Not to be Missed?
Volume: 10 Issue: 2
Author(s): Christian Urbanek, Frederick Palm and Armin J. Grau
Affiliation:
Keywords: Acute infections, influenza, stroke, risk factor, cerebral ischemia, vascular disease, vaccination, antivirals
Abstract: There is increasing evidence that acute bacterial and viral infection represent trigger factors that temporarily elevate the risk of ischemic stroke. During and after influenza epidemics vascular death rates and hospitalizations for stroke are increased. Influenza vaccination is an effective measure to reduce hospitalization and mortality in the elderly and work incapacity in adults of working age. Results of several observational studies support the hypothesis that influenza vaccination is associated with reduced odds of stroke. As randomized studies are lacking, a causal role of influenza vaccination in stroke prevention is not proven, however. According to current guidelines in many countries, that recommend the vaccination in all patients with chronic vascular disease, all patients with a history of stroke or TIA should receive an influenza vaccination annually. Furthermore, patients with diabetes mellitus or with a combination of risk factors that increase stroke risk should obtain the vaccination. In addition, there is evidence from observational data that the neuraminidase inhibitor oseltamivir reduces the risk of stroke within 6 months after influenza infection.
Export Options
About this article
Cite this article as:
Urbanek Christian, Palm Frederick and Grau J. Armin, Influenza and Stroke Risk: A Key Target Not to be Missed?, Infectious Disorders - Drug Targets 2010; 10 (2) . https://dx.doi.org/10.2174/187152610790963474
DOI https://dx.doi.org/10.2174/187152610790963474 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Circulating Meteorin-like Levels in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis
Current Pharmaceutical Design Antithrombotic Treatment in the Prevention of Ischemic Stroke
Current Drug Targets The Role of Combined Assessment of Defense Against Oxidative Stress and Inflammation in the Evaluation of Peripheral Arterial Disease
Current Molecular Medicine Traditional Chinese Medicine Network Pharmacology in Cardiovascular Precision Medicine
Current Pharmaceutical Design Targeting Peroxisome Proliferator-Activated Receptor Gamma for Generation of Antidiabetic Drug
Current Diabetes Reviews Adverse HBOC-Endothelial Dysfunction Synergism: A Possible Contributor to Adverse Clinical Outcomes?
Current Drug Discovery Technologies The Effects of Newer Beta-Adrenoceptor Antagonists on Vascular Function in Cardiovascular Disease
Current Vascular Pharmacology Review Metabolomics: A New Approach to Drug Delivery in Perinatology
Current Medicinal Chemistry Proteasome Modulator 9 and Depression in Type 2 Diabetes
Current Medicinal Chemistry Omentin: Linking Metabolic Syndrome and Cardiovascular Disease
Current Vascular Pharmacology Chymase Inhibitor As a Novel Therapeutic Strategy for Anti-Vascular Remodeling
Vascular Disease Prevention (Discontinued) Nature and Nurture in the Early-Life Origins of Metabolic Syndrome
Current Pharmaceutical Biotechnology Malignancy and Radiation-Induced Cardiotoxicity
Cardiovascular & Hematological Disorders-Drug Targets Uric acid and Metabolic Syndrome: What is the Relationship?
Current Rheumatology Reviews Circulatory Syndrome: An Evolution of the Metabolic Syndrome Concept!
Current Cardiology Reviews The Prothrombotic State in Hypertension and the Effects of Antihypertensive Treatment
Current Pharmaceutical Design Micro-RNA in Disease and Gene Therapy
Current Drug Discovery Technologies Doppler Haemodynamics of Cerebral Venous Return
Current Neurovascular Research Patent Selections
Recent Patents on Cardiovascular Drug Discovery Deranged Fractional Excretion of Magnesium and Serum Magnesium Levels in Relation to Retrograde Glycaemic Regulation in Patients with Type 2 Diabetes Mellitus
Current Diabetes Reviews